All News
Filter News
Found 541 articles
-
Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
12/5/2022
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage oncology company today announced preliminary results from the KRYSTAL-7 Phase 2 trial and KRYSTAL-1 Phase 1b cohort evaluating adagrasib (400mg twice daily) concurrently combined with pembrolizumab in patients for the treatment of first-line NSCLC harboring a KRASG12C mutation across all PD-L1 subgroups.
-
Amid rampant buyout speculation, Mirati Therapeutics reported that it will continue its final analysis of the Phase III SAPPHIRE trial following an interim survival analysis.
-
Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study
12/2/2022
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that based on the results of an interim analysis on overall survival, the registrational Phase 3 study evaluating sitravatinib in combination with nivolumab (OPDIVO®)1 in patients with second or third line non-squamous non-small cell lung cancer (NSQ-NSCLC) who have acquired resistance to prior therapy with chemotherapy and immune checkpoint inhibitor therapy (SAPPHIRE) will continue to the study's final analysis.
-
Mirati Therapeutics to Present Late-Breaking Combination Results and Host Virtual Investor Relations Event at ESMO IO
11/28/2022
Mirati Therapeutics, Inc. today announced a late-breaking presentation of concurrent combination results of adagrasib and pembrolizumab in first line advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation.
-
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)
11/17/2022
BeiGene Receives European Commission Approval for BRUKINSA ® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL).
-
Aadi Bioscience Presents PRECISION 1 Trial in Progress Poster and AMPECT Trial Final Analysis at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting
11/17/2022
Aadi Bioscience, Inc. today presented three posters on completed and ongoing clinical trials for nab-sirolimus at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting, taking place November 16-19, 2022 in Vancouver, Canada.
-
BeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood Cancers
11/10/2022
BeiGene Announces Brazil Approvals for BRUKINSA ® As a Treatment for Rare Blood Cancers.
-
Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update
11/9/2022
Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today provided a corporate update and announced financial results for the third quarter of 2022.
-
Mirati Therapeutics Appoints Alan Sandler, M.D., as Executive Vice President and Chief Medical Officer, Shares Update to Executive Leadership Team
11/8/2022
Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, announced the appointment of Alan Sandler, M.D., to the position of executive vice president and chief medical officer.
-
Mirati Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Updates
11/8/2022
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter of 2022 and recent corporate updates.
-
Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors
11/7/2022
Incyte (NASDAQ:INCY) and Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today announced a clinical trial collaboration and supply agreement to investigate the combination of INCB99280, Incyte’s small molecule PD-L1 inhibitor, and adagrasib, a KRASG12C selective inhibitor.
-
Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress
11/7/2022
Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced its financial results for the quarter ended September 30, 2022, and provided an update on corporate progress.
-
Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
11/3/2022
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended September 30, 2022, and highlighted recent progress.
-
BeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH Meeting
11/3/2022
BeiGene, (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced clinical and real-world data accepted at the 64th American Society of Hematology (ASH) Annual Meeting, scheduled for December 10-14, 2022, in New Orleans.
-
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
11/2/2022
BeiGene Receives European Commission Approval for BRUKINSA ® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma.
-
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - November 02, 2022
11/2/2022
Mirati Therapeutics, Inc. announced that the company granted equity awards to 13 new employees with a grant date of November 1, 2022, as equity inducement awards outside of the company's 2022 Equity Incentive Plan and material to the employees' acceptance of employment with the company.
-
BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America
10/26/2022
BeiGene today announced significant progress in efforts to unlock global opportunities for BRUKINSA® (zanubrutinib) with recent regulatory approvals in six Latin American countries.
-
Normunity Announces $65 Million Series a Financing to Expand the Frontier of Precision Immuno-Oncology With Immune Normalizer Therapies
10/25/2022
Normunity, Inc., a biotechnology company creating novel precision anti-cancer immunotherapies, today announced its launch and Series A financing of $65 million.
-
Mirati Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Updates
10/25/2022
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the third quarter of 2022 along with recent corporate updates on November 8, 2022.
-
Roche and Austria-based Hookipa Pharma tied up a licensing and research and development collaboration valued at more than $950 million focused on KRAS-mutated cancers.